Provider Briefing: The Carbidopa/Levodopa XR Shortage

The ongoing shortage of Carbidopa/Levodopa extended-release tablets continues to create challenges for providers managing Parkinson's disease patients in 2026. This briefing provides a concise overview of the current supply situation, prescribing implications, cost considerations, and practical tools to help your patients maintain access to treatment.

Whether you're a neurologist, movement disorder specialist, geriatrician, or primary care provider handling maintenance prescriptions, understanding the scope of this shortage — and the alternatives available — is essential for continuity of care.

Shortage Timeline and Background

Carbidopa/Levodopa extended-release tablets (formerly branded as Sinemet CR, now available only as generics) have experienced intermittent supply disruptions since the early 2010s. The current shortage, tracked by the American Society of Health-System Pharmacists (ASHP), affects multiple strengths and manufacturers:

• 2010s: Sporadic shortages linked to manufacturing quality issues and raw material constraints among a small number of generic producers
• 2020-2022: Pandemic-related supply chain disruptions exacerbated availability issues across many generic medications, including Carbidopa/Levodopa ER
• 2023-2024: Manufacturer discontinuations (including Sinemet CR brand by Organon) concentrated production among fewer generic makers, primarily Accord and Sun Pharma
• 2025-2026: Ongoing shortage listed on ASHP. Certain NDCs for both the 25/100 mg and 50/200 mg ER strengths remain in limited supply

The ASHP shortage listing notes that specific manufacturers have limited availability, and supply allocation varies by wholesaler and geographic region. The FDA has not announced a projected resolution date.

Prescribing Implications

The shortage raises several clinical considerations for prescribers:

Formulation Switching Is Not Straightforward

Carbidopa/Levodopa ER tablets and IR tablets are not bioequivalent. The ER formulation has approximately 70-75% bioavailability compared to IR tablets. When converting patients from ER to IR, dosage adjustments are necessary:

• Patients on ER 50/200 mg may need approximately 25/100 mg IR taken at shorter intervals (every 4-6 hours instead of every 6-8 hours)
• Titrate based on clinical response, not solely on mg-to-mg conversion
• Monitor for increased dyskinesia (due to higher peak Levodopa levels with IR) or wearing off (due to shorter duration)

Rytary Conversions Require Careful Calculation

If transitioning to Rytary (carbidopa/levodopa extended-release capsules), note that Rytary doses are not interchangeable with Sinemet CR or generic ER tablet doses. Amneal Pharmaceuticals provides a dosing conversion guide on the Rytary prescribing information. In general:

• Rytary provides both immediate and extended-release components, offering a different pharmacokinetic profile
• Prior authorization is typically required by most payers
• Cost may be a significant barrier for uninsured or underinsured patients ($800-$1,500/month without coverage)

Abrupt Discontinuation Risk

Remind patients that abrupt discontinuation of Carbidopa/Levodopa can precipitate a withdrawal syndrome resembling neuroleptic malignant syndrome (NMS), characterized by hyperthermia, muscular rigidity, altered consciousness, and autonomic instability. If a patient cannot fill their ER prescription, transitioning to an alternative formulation should be done promptly to avoid a treatment gap.

Current Availability Picture

As of early 2026, availability is mixed:

• Generic Carbidopa/Levodopa ER tablets (25/100 mg, 50/200 mg): Limited and inconsistent. Availability varies significantly by pharmacy, wholesaler, and region.
• Generic Carbidopa/Levodopa IR tablets: Widely available. Not affected by the same shortage.
• Rytary (brand ER capsules): Available through specialty and retail pharmacies. No shortage reported.
• Stalevo/generic Carbidopa/Levodopa/Entacapone: Generally available. May be an option for patients experiencing wearing off.
• Dopamine agonists (Pramipexole, Ropinirole): Widely available as generics. Useful as adjunct therapy but not a 1:1 Levodopa substitute.

Cost and Access Considerations

Understanding the cost landscape helps you guide patients toward affordable options:

• Generic Carbidopa/Levodopa ER: $50-$80 retail; as low as $29 with discount coupons (GoodRx, SingleCare)
• Generic Carbidopa/Levodopa IR: As low as $9/month with coupon
• Generic Stalevo (Carbidopa/Levodopa/Entacapone): $54-$100/month with coupon
• Rytary: $800-$1,500/month cash; manufacturer copay card available through PhilRx for commercially insured patients
• Dopamine agonists (generic): $10-$30/month

Most insurance plans cover generic Carbidopa/Levodopa ER as a Tier 1 or Tier 2 formulary item without prior authorization. Rytary typically requires prior authorization and often step therapy (trial of generic first). For patients with financial hardship, resources include NeedyMeds (needymeds.org), RxAssist (rxassist.org), and the Parkinson's Foundation.

Tools and Resources for Your Practice

Several resources can help you and your patients navigate the shortage:

Pharmacy Stock Checking

Medfinder for Providers allows you to search for Carbidopa/Levodopa XR availability by location. You can direct patients to pharmacies that currently have stock, reducing treatment gaps and phone-tag with pharmacies. Encourage patients to check how to check pharmacy stock online.

ASHP Shortage Database

The ASHP drug shortage database (ashp.org/drug-shortages) provides manufacturer-level updates on which NDCs are available, discontinued, or in limited supply. This can help you identify which manufacturer's product to specify on prescriptions.

Patient Education

Direct patients to these resources for additional support:

• How to find Carbidopa/Levodopa XR in stock near you
• Alternatives to Carbidopa/Levodopa XR
• How to save money on Carbidopa/Levodopa XR

Looking Ahead

Several developments may improve the supply situation over time:

• Additional generic manufacturers may receive FDA approval to produce Carbidopa/Levodopa ER tablets, diversifying the supply chain
• Advanced formulations like Vyalev (foscarbidopa/foslevodopa subcutaneous infusion) offer continuous Levodopa delivery for appropriate candidates with advanced disease
• FDA initiatives aimed at reducing drug shortages may help expedite approval of additional generic sources

In the meantime, proactive management — early refills, flexible prescribing, and awareness of alternatives — remains the most effective strategy.

Final Thoughts

The Carbidopa/Levodopa XR shortage is an ongoing challenge with no immediate resolution in sight. As a prescriber, your awareness of alternative formulations, conversion considerations, and cost-effective options directly impacts your patients' quality of life.

Equip your patients with tools like Medfinder to locate their medication, and stay current on shortage updates through ASHP. Parkinson's patients depend on consistent access to Levodopa — your proactive guidance can make the difference between a seamless transition and a dangerous treatment gap.

For a patient-facing version of this update, see Carbidopa/Levodopa XR shortage update: what patients need to know in 2026. For practical guidance on helping patients locate medications, read our provider's guide to helping patients find Carbidopa/Levodopa XR in stock.